Explore our comprehensive coverage of crispr, including scientific research, policy developments, environmental impacts, and solutions for a sustainable future.
The simultaneous commercialization of GLP-1 agonists, CRISPR gene therapies, and AI-driven drug discovery marks the end of exploratory biotech. This a...
Read Full Story →
Medical ResearchThe FDA's approval of the first AI-designed neurodegenerative drug and Phase 3 CRISPR data marks a d...
![[The Latency Arbitrage: CRISPR Point-of-Care Diagnostics and the Disruption of the PCR Monopoly]](https://www.crimaz.com/assets/images/no-image.png)
Public Health[The FDA's approval of the CRISPR-based SHERLOCK-Air point-of-care diagnostic marks the definitive d...
Medical Research[October 2026's convergence of CRISPR approvals, AI-designed Phase 3 molecules, and GLP-1 neuroprote...
Medical ResearchThe FDA's accelerated approval of in vivo CRISPR therapies and the NIH's aggressive reallocation of ...
Medical ResearchThe simultaneous validation of liquid biopsies, AI target discovery, and gene editing is permanently...
Public HealthThe convergence of WHO H5N1 protocol escalations, FDA CRISPR diagnostic clearances, and EU metabolic...
